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Abstract
There are many factors that can lead to underutilization of appropriate medical treatments for migraine, including a poor
understanding regarding the diagnostic features of migraine and available treatment options. The purpose of the present study
was therefore to assess migraine literacy and factors leading to different treatment decisions. Respondents were 229 university
students, both migraineurs and non-migraineurs, who completed online questionnaires which surveyed their knowledge of
migraines, and for migraineurs, their experiences of migraine andmigraine treatment.While migraineurs had significantly greater
migraine literacy than non-migraineurs according to the questions asked, knowledge was incomplete in both groups. The
majority of migraineurs who used prescription medication for acute pain relief found such medications to be very effective,
and for those who did not use such medications, one in five cited the reason was that they did not know that such medications
were available. The imperfect migraine literacy, both in terms of diagnostic features and available treatments, highlights avenues
for future public health awareness campaigns.
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Introduction
Despite the suffering and disability that migraine conditions
bring, migraine is often underdiagnosed and undertreated in
clinical settings [1–3]. One key reason for this may be a poor
understanding in the general public of the diagnostic features
of migraine, in particular, the symptoms that facilitate differ-
ential diagnosis of migraine versus non-migraine headache.
For example, migraines are often mistaken for sinus head-
aches [4, 5]. However, best-practice management of migraines
typically requires migraine-specific treatments, such as
triptans [6, 7]. Therefore, if patients presenting in clinical set-
tings are not aware of the defining differences between mi-
graine and non-migraine headache, patients may not articulate
these symptoms or request appropriate treatment, then some
of the shortcomings of treatment in clinical settings could stem
from these issues. The goal of the present study was therefore
to examine the role of migraine literacy in a non-clinical pop-
ulation. That is, if migraine literacy is limited, future interven-
tions aimed at raising awareness of the diagnostic features of
migraine and available treatments could improve clinical out-
comes if patients understand how their symptoms relate to
migraine diagnosis and available treatments, and are therefore
better placed to advocate for their own care.
In the present study, migraine literacy and other potential
barriers to full utilization of effective treatment were assessed
in a university student sample. A university sample is, by
definition, a highly educated sample. This means that this
group likely represents one of the maximum levels of literacy:
any deficits of knowledge observed in this sample are only
likely to be accentuated in other groups. Therefore, the present
study examined migraine literacy and treatment experiences
and decisions in a university sample.
Research Highlights
• Found higher rates of migraine literacy among migraineurs than non-
migraineurs
• Identified key areas of incomplete migraine literacy regarding both
diagnosis and treatment that should be targeted in future public health
awareness campaigns
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Method
Respondents were recruited to complete a Health
Questionnaire via an electronic participation website, where
students enrolled in eligible courses were offered course credit
in exchange for participation. There were no eligibility criteria
for participation imposed. The questionnaire was adminis-
tered online via Qualtrics. All provided informed consent pri-
or to participation and all aspects of the study were approved
by the Australian National University (ANU) Human
Research Ethics Committee (Protocol number 2018/034).
The sample size was not prescribed; instead, it was determined
by the number of participants who volunteered throughout the
semester that the study was available. The semester that the
study was available was semester 1, 2018 (February–
June 2018).
The questionnaire was divided into three sections: two de-
mographic items were included to characterize the sample,
then the first major block assessed participants’ general liter-
acy and knowledge regardingmigraines, and the secondmajor
block collected information about their own experiences of
migraines and treatments. The first demographic item asked,
“What gender do you identify as?”, and the response options
were male, female, and other. The second asked, “What is
your age (in years)?”, a numeric response (between 0 and
100) was requested.
Block 1: Migraine Knowledge These questions were designed
to assess participants’ knowledge of the defining features of
migraine headache, with a particular focus on differentiating it
from non-migraine headache. Questions 1–5 (Q1–Q5) made a
statement, and participants were asked to indicate whether
they thought it was True or False. For example, Q1 reads
“Migraines have the same symptoms as other headaches.”
The full questionnaire and its response format can be found
in Appendix A. The facts about migraine for these and other
questions were obtained from the World Health Organization
[8]. Note that the correct answers constitute a mix of true and
false, so that a response bias toward true/false could not sys-
tematically affect the accuracy of responses to these items.
Q6–Q9 and Q11–Q14 asked to what extent a series of
characteristics were associated with migraine (e.g., nausea,
seizure, aura, for full list; see Appendix A). The response
options were as follows: Is a defining characteristic of mi-
graine (a headache would not be considered a migraine with-
out this feature)/Is commonly associated with migraine/Is not
commonly associated with migraine/Is never associated with
migraine. For the purposes of scoring, the first two responses
were treated as equivalent (i.e., associated with migraine) and
the second two responses were treated as equivalent (i.e., not
associated with). Q15 asked how long a migraine episode or
attack typically lasts, from the following options: Seconds to
minutes, Minutes to Hours, Hours to several days, and Days
to weeks. Q10 and Q16 were control response check ques-
tions. Q17–Q19 probed participants’ awareness about the
availability of different migraine treatments. They asked a
series of statements about medication for migraine requiring
true/false responses. For example, Q17 stated “Prescription
medications (i.e., those that require a script from a doctor)
are available, which can work in the short term to relieve
migraine symptoms.”
Block 2: Migraine and Treatment Experience The second ma-
jor block of questions asked participants about their experi-
ences of migraine (if any) and treatments that they had used,
and their reasoning and decision-making surrounding treat-
ment options (see Appendix A for full list of questions). In
particular, the goal was to identify common barriers to
accessing effective treatment. In this block, Q1 asked, “Have
you ever had a migraine headache?”, with the response op-
tions Yes, No, and Have had a headache but do not know
whether it was a migraine available. All of the following
questions were asked if and only if respondents selected Yes
or Do not Know to Q1. Q2 asked, “Have you been diagnosed
with migraine by a health professional (e.g., your doctor or a
specialist)?” The response options for this question were Yes
and No. Next, participants were presented with this informa-
tion and instruction on-screen: “For the following questions, if
you have ever had a migraine headache, then please answer
the following questions in relation to your migraine head-
aches. If you have had a headache but are unsure whether it
was a migraine, then please answer the following questions in
relation to your headaches.”
Q3–Q8 were drawn from the Migraine Disability
Assessment (MIDAS) questionnaire [9] and assessed the fre-
quency of migraine experience and the resulting disability. For
instance, Q3 asked, “On how many days in the last 3 months
did you miss work or university because of your headaches?”,
while Q7 asked, “On how many days in the last 3 months did
you have a headache (If a headache lasted more than 1 day,
count each day)”. Q9–Q17 collected information about re-
spondents’ experience with treatments for their headaches.
Q9 asked, “When you have a migraine attack, do you use
over-the-counter (i.e., purchased from a pharmacy or other
store without a script from a doctor) medications to relieve
your migraine)?” The response options were Yes and No. If
respondents answered No to Q9, then their reasons for not
accessing such medications was assessed, whereas if they an-
swered Yes to Q9, then their experience of the treatment effi-
cacy was probed. Similarly, Q12 asked, “When you have a
migraine attack, do you use prescription medication (for
which a script from a doctor is required) to relieve your mi-
graine?”. The response options were Yes and No.Respondents
were then asked either about the effectiveness of this medica-
tion (if they responded Yes), or the reasons why they had not
accessed such medications were probed if they answered No.
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Q15 asked, “Do you use prescription medication to reduce or
prevent the recurrence of migraine attacks?”. The response
options were Yes and No. If respondents answered Yes, then
they were asked about the effectiveness of the treatment,
whereas if respondents answered No, then they were asked
to indicate why they had not accessed such treatments. Q18
asked, “Please select ‘daily headache’ below,” where the re-
sponse options were Monthly headache/Weekly headache/
Daily headache/Yearly headache. Q19 was an open-ended
question that asked participants to share any other thoughts,
reflections, or insights they would like about migraines that
they would like.
Statistical Procedure Statistical analysis was conducted in
Statistical Package for the Social Sciences (SPSS). The
“Knowledge Metric” was computed as the mean accuracy of
respondents’ answers in each of the three groups across the 17
items in block 1 (excluding the two control check items) that
assessed migraine-related knowledge. This Knowledge
Metric variable was non-normally distributed (Shapiro-Wilk
p < 0.001), and therefore, non-parametric analyses were used
to compare the groups (i.e., Kruskal-Wallis tests where three
groups are compared and Mann-Whitney U tests when two
groups are compared). All of the statistical analyses were two-
tailed tests, where the critical alpha level was 0.05.
Data Availability
Raw data are available here: https://osf.io/skqbh/.
Results
Screening and DemographicsA total of 229 respondents com-
pleted the questionnaire. There were no missing data. There
were three screening questions in the questionnaire. Three
respondents were excluded from further analysis because they
did not respond appropriately to the first two check questions
(the first asked them to select the word “Migraine” from four
possible response options, and a second asked participants to
select “False” from the options true, neither true nor false, and
false). Although a third question was also included in the final
part of the questionnaire, it appeared that some respondents
may have misread the question. It asked respondents to select
“daily headache” from amongst four options (Monthly
headache/Weekly headache/Daily headache/Yearly
headache). In contrast to the first two questions, more than a
few respondents answered this question incorrectly, despite
providing detailed comments in subsequent sections, indica-
tive of the fact that they were not unduly rushing their re-
sponses. Instead, since this question appeared amongst others
asking individuals about their experiences of migraine, it
seems likely that some of these respondents misread this ques-
tion and were instead reporting how often on average they
experienced headaches. Therefore, no respondents were ex-
cluded for not responding “Daily headache” to this question.
The sample contained 172 females and 54 males, with a mean
age of 20.03 years (SD = 4.69). The respondents were classi-
fied into one of three groups: migraineur (N = 59), unsure
(N = 92), and non-migraineur (N = 75) on the basis of their
response to the question, “Have you ever had a migraine head-
ache,” where the response options were yes (= migraineur),
Have had a headache but do not know whether it was a mi-
graine (= unsure), and no (= non-migraineur). This means that
26% of respondents were definite migraineurs, 41% unsure,
and 33% non-migraineurs.
Knowledge Assessment Seventeen questions were used to as-
sess respondents’ migraine and headache-related knowledge
and compute the Knowledge Metric. The results are reported
in Table 1. A Kruskal-Wallis test revealed that the migraineur,
unsure, and non-migraineur groups scored significantly differ-
ently across this Knowledge Metric (p < 0.001). Subsequent
Mann-Whitney U tests revealed that migraineurs (M = 82%)
scored higher than both non-migraineurs (M = 77%),
U= 1591.00, p = 0.005, and the unsure group (M = 75%),
U = 1658.00, p < 0.001, which did not reliably differ from
one another, U = 3119.50, p = 0.280.
Migraineurs scored slightly higher than either of the other
two groups in response to Q1 regarding whether migraines
have the same symptoms as other headaches. For all groups,
however, even for migraineurs, 20% of the sample were not
correct on this point, and 24% and 32% of the non-migraineur
and unsure groups, respectively. Respondents were reason-
ably accurate in their responses to Q2–Q4, whereas Q5 re-
garding the laterality of migraine pain produced lower accu-
racy. Chance-level performance (i.e., that which would be
achieved purely by guessing) to these T/F questions would
be 50%. For the non-migraineurs, accuracy was only 59% in
response to this question, versus 61% and 70% for
migraineurs. This highlights relatively low levels of knowl-
edge regarding the fact that migraine is typically unilateral and
that this can be a distinguishing feature from other headaches.
The fact that nausea (Q6), sensitivity to light (Q8), sensitivity
to sound (Q9), and pulsating headache (Q11) are associated
with or defining features of migraine compared with other
types of headache, whereas seizure (Q7) and loss of con-
sciousness (Q12) are not, was all answered with a reasonable
degree of accuracy (70–93%). The association of sensory
disturbances (often visual) such as aura with migraine
(Q13) separated migraineurs (92%) from non-migraineurs
(69%) and the unsure group (65%) by over 20 percentage
points.
All groups were below chance in their accuracy regarding
the fact that migraine headache is often aggravated by a
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routine physical activity (Q14, 41–48%). Accuracy was also
low in response to Q15 regarding the duration of a typical
migraine, with only 63% of migraineurs correctly identifying
the hours to several days’ duration, but the unsure group
(38%) and non-migraineurs (49%) scored even lower. While
the majority of migraineurs and non-migraineurs selected the
correct answer, the next most common response for both
groups was Minutes to Hours. This was also the most com-
mon response for the unsure group. This suggests that those
who have had less experience with migraine or who feel less
sure about its diagnostic features are likely to underestimate
the duration of the average migraine attack. All groups
showed a high level of awareness that prescriptions medica-
tions are available to offer short-term relief to migraine symp-
toms (Q17, 93–96%). The awareness was somewhat lower
regarding the potential dangers of medication overuse (Q18,
75–79%) and the availability of prophylactic medication
(Q19, 71–80%).
Experience of Migraine and Migraine Treatment The ques-
tions in block 2 related to respondents’ experience of migraine
and migraine treatment. The results for these are shown in
Table 2 (migraine experience) and Table 3 (treatment
experience).
None of the unsure group had been diagnosed with mi-
graine by a health professional (Q2), compared with 37% of
the migraineur group. Q3–Q8were from theMIDAS to assess
migraine disability. The responses for the migraineur group
versus the unsure group were compared statistically across
these questions, and the migraineur group showed significant-
ly higher levels of disability and pain than the unsure group
(p < 0.05) according to Mann-Whitney U tests for all except
for the question regarding Q4. Despite the mean responses for
the two groups being quite different on this question, there
was considerable variability around the migraineur mean
(note that SD is more than twice the mean) which would have
contributed to this null result. This may be because making an
assessment about how productivity is impacted is more diffi-
cult and varies across individuals to a greater extent than a
question about how often one missed out on activities or suf-
fered pain.
Just over half of the migraineurs used over-the-counter
(OTC) medication to treat their pain, compared with just over
a third of the unsure group. Of those who did use OTC med-
ication, the majority of both migraineurs (58%) and the unsure
group (71%) found them to beModerately effective. The most
commonly selected reasons for not using such medication for
the migraineur group were My headaches are not severe
enough to need them (36%) and They do not relieve my
migraine (29%), and for the unsure group wereMy headaches
are not severe enough to need them (71%). A total of 11% of
the migraineur group and 8% of the non-migraineur group
were unaware that such medications were available.Ta
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Only aminority of the migraineurs (22%) and unsure group
(9%) used prescription medication to relieve their migraine
attack. Of the migraineurs, the most commonly reported level
of effectiveness of such prescription medications was Very
effective (46%), whereas for the unsure group, the most com-
monly reported level of effectiveness was Moderately
effective (75%). The most commonly reported reason for not
using suchmedication amongst the migraineurs wasMy head-
aches are not severe enough to need them (39%) and I did not
know that they were available (20%), compared with My
headaches are not severe enough to need them (81%) for the
unsure group. Similarly, only a minority of migraineurs (12%)
and the unsure group (9%) had used prescription medication
to reduce or prevent the recurrence of migraine attacks. For
migraineurs, the most commonly reported level of effective-
ness of such medications was Moderately effective, for both
the migraineur (43%) and the unsure (75%) groups. For those
who did not use them, the most commonly reported reason for
both groups (48% and 73%, respectively) was My headaches
are not frequent enough to need them.
Discussion
Migraine is a disorder associated with considerable disability,
suffering, and cost [10]. While promising new drugs are being
developed [11], these do not address the substantial problems
surrounding appropriate diagnosis and treatment of migraine
that still remain. Therefore, there were two main purposes for
the present study. First, this study sought to examine migraine
literacy in a university sample, comparing individuals who
had and had not experienced migraine headache. There were
moderate levels of migraine literacy, and the questions asked
significantly differentiated those with migraine from those
who had not or were unsure about whether they had experi-
ence migraine headache. The fact that the migraineurs showed
the highest levels of headache literacy likely stems from ex-
posure to information from health professionals during the
process of diagnosis and treatment, in addition to individuals’
own research to understand the nature of their symptoms. That
said, with average accuracy for the migraineurs and the other
groups alike being well off 100%. Approximately one in five
migraineurs and one in four non-migraineurs were incorrect
regarding whether headaches and migraines have the same
symptoms. This is important because accurate diagnosis de-
pends on differentiating migraine from other types of head-
ache. This illustrates the need to more effectively disseminate
information regarding the unique diagnostic hallmarks of mi-
graine. For example, the fact that migraine pain is typically
unilateral and aggravated by routine physical activity was not
well understood, and the knowledge that migraine is associat-
ed with aura clearly separated those with migraine from the
others in the sample. The finding that this university sample—Ta
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by definition, a group with a high level of education—still
lacked full knowledge regarding the identifying features of
migraine suggests that, if anything, migraine literacy rates
are likely to be even lower in the general population. This
highlights opportunities for promoting greater health and
headache literacy.
It was also concerning that approximately one in five
migraineurs were not aware of the dangers of medication
overuse. Overuse of acute pain-relief medications for migraine
such as triptans leads to a form of chronic migraine known as
medication-overuse headache which is a prevalent and wide-
spread health problem [12]. The results of this questionnaire
suggest that inadequate understanding of this danger may con-
tribute to this problem. Therefore, there is a need for clearer
and more effective dissemination of information around the
dangers of medication overuse.
Second, the study was designed to examine individuals’
experience of migraine and its treatment, with a view to iden-
tifying barriers to individuals accessing effective treatments.
When it came to OTC treatments, some migraineurs felt that
their headaches were not severe enough to warrant such treat-
ments; however, another commonly cited reason was that they
were not effective in relieving migraine. In contrast, the ma-
jority of the migraineurs who used prescription treatments for
their pain found them to be very effective. This suggests that
prescription medications best served migraineurs pain-
management needs when intervention was called for.
However, of the migraineurs who did not use such treatments,
one in five cited the reason being that they were unaware that
such treatments were available. For all treatments, both acute
and prophylactic, respondents only infrequently selected rea-
sons such as side-effects and costs as barriers to treatment.
Again, this highlights that there are improvements that can
be made regarding public awareness of the availability and
utility of such treatments to migraineurs, so that patients can
better articulate their critical symptoms and advocate for their
own care.
This study contributes to and extends upon the existing
literature in important ways. Previous studies have revealed
that migraine is often poorly understood and misdiagnosed in
primary care settings [13, 14]. For instance, one study found
that themajority of primary health care professionals were not
aware that opioids can cause medication-overuse headache
[13], thereby perpetuating and exacerbating the issue for
which treatment is sought. Similarly, it is estimated that half
of all migraineurs remain undiagnosed [15]. In contrast, im-
provements in patients’ recognition of migraine-specific treat-
ments have been documented after consultation with a spe-
cialist (i.e., neurologist) [16]. While this indicates that consul-
tation with specialist healthcare professionals can be benefi-
cial, it is also important to address general knowledge of mi-
graine symptomology and treatment options, for example, via
public health campaigns. This is because without this
knowledge, there are significant potential barriers to individ-
uals accessing the right care, which balances both the benefits
and risks of different treatment approaches. If neither the pa-
tient nor primary health care professional recognizes mi-
graines for what they are, then the patient is less likely to
receive the appropriate care.
This study had some limitations which are important to
acknowledge. First, the sample consisted of university stu-
dents. This represents a highly educated sample, and there-
fore, if anything, may underestimate issues with migraine lit-
eracy. That is, migraine literacy may be even lower in the
general population compared with this sample. However, a
number of gaps were identified in migraine literacy here,
and therefore, a general population sample would likely serve
to further highlight the need for future interventions to target
these knowledge gaps. Second, this study was advertised to
potential volunteers as a Health Questionnaire. While no
mention was made of migraine specifically, it is possible that
this was of particular interest to individuals with health issues,
including migraine. This may have elevated the number of
migraineurs in the sample. Indeed, the rates of migraine-
reporting individuals (i.e., 26% definite migraineurs) are con-
siderably above typical base rates for the condition in the
general population, where estimates between 5 and 12% have
been reported [17]. This could reflect that university students
may be at elevated risk of migraine. This is plausible because
university students are a high-risk group for psychological
conditions [18, 19], which are often co-morbid with migraine
[20]. Alternatively, it could simply reflect the fact that
migraineurs (versus non-migraineurs) were disproportionately
drawn to participate in this study. Third, this study relied on
participants’ self-report of their knowledge and experience. It
would be useful to obtain converging evidence, for example,
from health professionals regarding participants’ diagnoses.
That said, however, clinicians typically rely heavily on partic-
ipants’ self-report in both diagnosis (e.g., using the MIDAS or
migraine diaries to assess frequency and severity) and treat-
ment (e.g., determining whether a patient is satisfied with the
efficacy of a particular treatment) [21, 22]. At present, there is
no objective measurement of migraine, and therefore, self-
report represents a reasonable method for research in this area.
Conclusion
In conclusion, this study identified some particular gaps and
therefore avenues for future interventions to target regarding
migraine symptomology and treatment literacy. In particular,
public health campaigns should be targeted at improving
awareness of some of the features that differentiate migraine,
as well as both the availability but necessary precautions of
medication options for migraine treatment.
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